Tennis elbow indication sought for OssaTron:
This article was originally published in Clinica
Executive Summary
HealthTronics Surgical Services has move to expand the US market for its shock wave device by submitting a premarket approval application to the FDA to use the product as a treatment for tennis elbow. The OssaTron device uses high-energy shock waves to cause microscopic damage to the scar tissue that forms in the elbow as a result of the condition. The therapy leads to the growth of new blood vessels in the area and allows tissue-healing cells to repair the chronic injury, says the Marietta, Georgia firm, which sells the device in the US for treating plantar fasciitis.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.